On March 18, 2026, REGENXBIO Inc. entered into a Settlement and Release Agreement with GlaxoSmithKline LLC to resolve a dispute over sublicense fees under their 2009 License Agreement. The Company will pay $10.0 million to GSK within three business days, securing mutual releases of past claims and certain future claims while continuing existing payment practices.
Key takeaways
Entered Settlement and Release Agreement with GlaxoSmithKline LLC on March 18, 2026
Payment of $10.0 million to GSK within three business days for alleged underpayment of sublicense fees
Resolves dispute related to License Agreement dated March 6, 2009, as amended on April 15, 2009
Mutual releases of all past claims and certain specified future claims under the GSK-REGENXBIO Sublicense
Company to continue paying GSK using existing allocation methodology